• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    bioAffinity Technologies, Inc. - Warrant (NQ:BIAFW)

    0.2448 UNCHANGED
    Delayed Quote Updated: 10:36 AM EST, Nov 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 29
    Open 0.2448
    Bid (Size) 0.1610 (100)
    Ask (Size) 0.2449 (300)
    Prev. Close 0.2448
    Today's Range 0.2448 - 0.2448
    52wk Range 0.0600 - 0.9800
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month
    From bioAffinity Technologies, Inc.
    Via Business Wire

    Performance

    52-Week Range 75.0% below 52-week high
    0.2448
    0.0652W Low 0.9852W High

    bioAffinity Technologies, Inc. - Warrant (BIAFW) traded between $0.06 and $0.98 over the past 52 weeks and last traded at $0.24, 75.0% below its 52-week high.

    Past 12 Months
    N/A
    -52.9%
    +308.0%
    -21.2%
    -4.7%
    -2.6%
    1W  
    1M -$0.28
    3M +$0.18
    6M -$0.07
    YTD -$0.01
    1Y -$0.01

    BIAFW was -2.6% over the past year, -21.2% over six months, -4.7% year to date.

    12 Months vs Market
    BIAFW
    -2.6%
    DIA
    +9.2%
    SPY
    +9.7%
    QQQ
    +7.3%
    IWM
    +13.9%

    Over the past 12 months BIAFW returned -2.6% versus DIA (Dow) +9.2%, SPY (S&P 500) +9.7%, QQQ (Nasdaq 100) +7.3% and IWM (Russell 2000) +13.9%.

    Volume & Liquidity 0.00× 3-mo avg
    Today 29 3-mo avg 8.7K
    1W
    29.0
    1M
    1.4K
    3M
    8.7K
    6M
    5.5K
    YTD
    4.3K
    1Y
    3.9K

    BIAFW most recently traded 29 shares against a 3-month average daily volume of 8.7K.

    More News

    Read More
    News headline image
    bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Closing of $3.2 Million Offering
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Pricing of $3.2 Million Offering
    From bioAffinity Technologies, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is bioAffinity Technologies, Inc. - Warrant publicly traded?
    Yes, bioAffinity Technologies, Inc. - Warrant is publicly traded.
    What exchange does bioAffinity Technologies, Inc. - Warrant trade on?
    bioAffinity Technologies, Inc. - Warrant trades on the Nasdaq Stock Market
    What is the ticker symbol for bioAffinity Technologies, Inc. - Warrant?
    The ticker symbol for bioAffinity Technologies, Inc. - Warrant is BIAFW on the Nasdaq Stock Market
    What is the current price of bioAffinity Technologies, Inc. - Warrant?
    The current price of bioAffinity Technologies, Inc. - Warrant is 0.2448
    When was bioAffinity Technologies, Inc. - Warrant last traded?
    The last trade of bioAffinity Technologies, Inc. - Warrant was at 11/02/26 10:36 AM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.